Results 101 to 110 of about 3,351 (178)

Kinase-Impaired BTK Mutations Are Susceptible to Clinical-Stage BTK and IKZF1/3 Degrader NX-2127 [PDF]

INTRODUCTION: Bruton’s tyrosine kinase (BTK) is a nonreceptor kinase in the B cell receptor (BCR) signaling cascade critical for B cell survival. As such, chronic lymphocytic leukemia (CLL) and other B cell cancers are sensitive to inhibition of BTK ...
Abdel-Wahab, Omar, Affer, Maurizio, Alencar, Alvaro, Auger, Paul, Barrientos Risso, Carla, Bourcier, Jessie, Bousquet, Hugo, Brathaban, Nivetha, Bravo, Brandon, Brown, Robert J, Chirino, Alexandra, Gajewski, Stefan, Garippa, Ralph, Gessner, Melissa, Guiducci, Cristiana, Han, Cuijuan, Hansen, Gwenn M, Iuliano, James N, Jahn, Jacob, Kane, Tim, Kim, Won Jun, Linley, Adam, Lu, Hao, Mato, Anthony R, Mehta, Sanjoy, Mi, Xiaoli, Montoya, Skye, Mukerji, Ratul, Nawaratne, Vindhya, Notti, Ryan Q, Noviski, Mark, Pardo, Alejandro, Pardo, Gabriel, Pena-Velasquez, Camila, Powers, Janine, Reddy, Panga Jaipal, Rhodes, Joanna M, Roeker, Lindsey E, Sanchez Garcia de Los Rios, Mateo, Sievers, Quinlan, Skånland, Sigrid S, Sondhi, Anya K, Soni, Rajesh Kumar, Tan, Ying Siow May, Taylor, Justin, Thompson, Meghan C, Totiger, Tulasigeri M, Tsai, Daniel, Urban, Aleksandra, Wang, Eric, Ye, Jordan, Yung, Stephanie, Zelenetz, Andrew D   +52 more
core   +1 more source

Iron Deficiency Anemia in Children With Short Bowel Syndrome [PDF]

N
Fawole, Rasheedat Yetunde
core   +2 more sources

Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial [PDF]

, 2023
Linton, Kim
core   +1 more source

P109 | A MULTICENTER RETROSPECTIVE ANALYSIS OF ZANUBRUTINIB THERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA ("PARTENOPE PROJECT"): REPORT FROM THE CAMPANIA NETWORK ON CHRONIC LYMPHOCYTIC LEUKEMIA

Haematologica
Zanubrutinib, a selective second-generation covalent Bruton tyrosine kinase inhibitor approved in various B-cell malignancies, has showed its activity in B-cell chronic lymphocytic leukemia (CLL).
G. D'arena, M. Lucignano, A. Fresa, G.R. Nunziata, F. Graziani, V. Amico, M. Troiano, R. Fontana, C. Giordano, G. Svanera, V. Sammartano   +10 more
doaj  

Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia. [PDF]

Future Oncol
Shadman M, Chanan-Khan A, Campbell D, Xue M, Massoudi M, Williams R, Yang K, Tam CS.   +7 more
europepmc   +1 more source

Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database [PDF]

Brown J. R., Cohen A., Ghia P., Jurczak W., Kahl B. S., Lamanna N., Ma H., Paik J., Qiu L., Robak T., Salmi T., Shadman M., Tam C. S., Tedeschi A., Wang L., Zhang J., Zhang M.   +16 more
core   +1 more source

Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study. [PDF]

Blood Adv
García-Sanz R, Owen RG, Jurczak W, Dimopoulos MA, McCarthy H, Cull G, Opat SS, Castillo JJ, Kersten MJ, Wahlin BE, Grosicki S, Prathikanti R, Tian T, Allewelt H, Cohen AC, Tam CS.   +15 more
europepmc   +1 more source

First-line treatment for CLL in the era of targeted therapy. [PDF]

Blood Cancer J
Davids MS, Stilgenbauer S, Tam CS.
europepmc   +1 more source

Exploring the role of IRF4 in the sensitivity of mantle cell lymphoma cells to Bruton\u27s Tyrosine Kinase inhibitors [PDF]

Introduction and aim: Mantle cell lymphoma (MCL) is an aggressive subtype of B-cell lymphoma. Therapy using Bruton’s tyrosine kinase (BTK) inhibitors has improved clinical outcomes but primary and secondary resistance to BTK inhibitor (BTKi) therapy ...
Portnojs, Artjoms
core   +1 more source

Zanubrutinib for the treatment of cutaneous relapse of systemic marginal zone lymphoma: A case report. [PDF]

JAAD Case Rep
Osman S, Street L, Hardin J.
europepmc   +1 more source